SPRCライブシグナル | Getagraph.comで利益を最大化

売る 119641 min ago

@ $3.99

発行日: 6 2月 2024 @ 23:45

リターン: -65.40%

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:27):

Stats
本日の出来高	99 219.00
平均出来高	834 604
時価総額	3.38M
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00800 (0.58%)

ボリューム相関

長: -0.10 (neutral)

短: -0.23 (neutral)

Signal:(41.045) Neutral

SciSparc Ltd. 相関

10 最も正の相関
MXIM	0.937
HYMC	0.83
LSBK	0.801

10 最も負の相関
IKNX	-0.851
APOP	-0.841
CMLF	-0.826
MAGS	-0.805
MOSY	-0.804

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

SciSparc Ltd. 相関 - 通貨/商品

0.90
( strong )

0.00
( neutral )

0.79
( moderate )

-0.74
( moderate negative )

-0.81
( strong negative )

SciSparc Ltd. 財務諸表

Annual	2023
収益:	$2.88M
総利益:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2023
収益:	$2.88M
総利益:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2022
収益:	$1.35M
総利益:	$1.03M (76.10 %)
EPS:	$-14.73

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

SciSparc Ltd.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.